Navigation Links
IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Date:3/27/2008

TORONTO, March 27 /PRNewswire/ - IntelliPharmaCeutics Ltd. (Delaware) is pleased to announce significant results from a recently completed pilot clinical trial for its new abuse-resistant, alcohol-resistant once-a-day oral oxycodone formulation by its operating company IntelliPharmaCeutics Corp. of Toronto ("IntelliPharmaCeutics" or the "Company"). The product is covered by pending patent applications for its novel ReXista(TM) abuse and alcohol resistant drug delivery technology. It is one of the Company's line of in-house analgesic products in development for the management of moderate to severe chronic and acute pain.

The ReXista(TM) oxycodone product is a novel dosage form, designed to be resistant to abuse by oral ingestion when crushed or chewed, by injection when combined with solvents, and by nasal application when crushed or powdered. The abuse of this important pain relief drug has been well documented over many years.

The ReXista(TM) oxycodone product is also designed to resist release of the entire daily dose when consumed with alcohol in any quantity, a problem so serious with some opioid drugs such as hydromorphone that their use has been limited or curtailed by the FDA.

The product has been subjected to rigorous in-vitro testing and has met its design criteria for dissolution profiles and in-vitro resistance to simulated abuse. Based on these initial results, the product is expected to be effective for once-a-day dosing in the management of pain. It is also expected that it will resist abuse by oral, nasal or intravenous administration and resist unintended total dose release in the presence of alcohol.

The initial pilot clinical trial was designed to compare the pharmacokinetic characteristics of the IntelliPharmaCeutics ReXista(TM) oxycodone product, in a once-a-day 40mg dosage format, with a currently marketed branded oxycodone product, Purdue Pharma's Oxycontin(R), in a twice-a-day 20mg dosage format, under fasted
'/>"/>

SOURCE IntelliPharmaCeutics Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...Blue Marble Energy Corp. announced today that the ...y (OPDA) were recently awarded $2 million by Washi...ard (CERB) in a private/public partnership to cons...efinery in Lincoln County, WA. ,, "This inves...our biorefinery and bring over 70 green jobs to Li...
(Date:11/24/2009)...as been met for patients with advanced-stage, o..., Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentari... a global biopharmaceutical company focused on end...ive efficacy data from a Phase 2 study with its ta...erly AN-152), in patients with advanced or recurre...
(Date:11/24/2009)...ire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ: SH...any, today,announced that it has submitted a MAA t...alfa, the company,s enzyme replacement therapy in ...sease. This is the third marketing,application for...previous,submissions in the United States and Cana...
(Date:11/24/2009)...PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nas...omic Health,s Executive Chairman, will present at ...ce in New York City on Tuesday, December 1, 2009 a...sequently archived webcast of the presentation, vi...th,s website at http://investor.genomichealth.com...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...st time,researchers at North Carolina State Univer..." spheres whose halves are physically or chemicall...ove like stealthy,submarines when an alternating e...he particles., A paper describing the research, p...Review Letters, advances knowledge about how poten...
...Expose Highlights Urgent Need for ...., Feb. 29 CNN,s recent expose on,asbestos in chi...t the,deadly carcinogen is virtually everywhere in... heavily in Navy ships and shipyards; in,workplace..., flooring,roofing materials, and cement pipes; in...
...orporation,(Nasdaq: ACEL ) today announced that i...m. EST on Friday, March 7. During the call, Kuslim...awrence A. Kenyon, chief operating,officer and chi...Alfacell,s,financial performance for the fiscal se...ticipate in the live conference call, U.S. residen...
Other Biology Technology:'Two-Faced' Particles Act Like Tiny Submarines 2'Two-Faced' Particles Act Like Tiny Submarines 3Calling for a Cure 2Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast 2
(Date:11/26/2009)... November 2009 What are the bare essentials of li...uce a cell that can survive on its own? Can we des...and how an entire organism functions as a system? ...ts in a partnership between the European Molecular... and the Centre de Regulacio Genmica (CRG) in Barc...
(Date:11/25/2009)...irefighters, police officers and ambulance workers...de Center complex. They battled to save people fro...rs, tackled fires and evacuated as many people as ... 17,000 people. And making their jobs even harder ... workers and their relatives jammed mobile network...
(Date:11/25/2009)... you eat may be just as vital to your health as wh...e for Biological Studies. Their experiments in mic...usands of genes in the liverthe body,s metabolic c...d not by the body,s circadian clock as conventiona...the activity of a large number of genes completely...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3Hypertronics HyperGrip 28R 29 and D Series Connectors Selected for SynCardias Total Artificial Heart 54069 1Hypertronics HyperGrip 28R 29 and D Series Connectors Selected for SynCardias Total Artificial Heart 54069 2Centage Corporation Announces Planning Maestro Business Performance Management Software for Mid Market Enterprises 13475 1Centage Corporation Announces Planning Maestro Business Performance Management Software for Mid Market Enterprises 13475 2Centage Corporation Announces Planning Maestro Business Performance Management Software for Mid Market Enterprises 13475 3Boston University Launches Online Component of Sargent Choice 54061 1Boston University Launches Online Component of Sargent Choice 54061 2Boston University Launches Online Component of Sargent Choice 54061 3
...ccurate estimates of the causes of child deaths to...ET, reveal that worldwide more than 70% of the 10....ributable to six causes: pneumonia (19%), diarrhoe...a (10%), preterm delivery (10%), and asphyxia at b... School of Public Health, Baltimore, USA) and coll...
...nth,s issue of the freely available online journal...ues from Kilifi, Kenya, show that the protection a...le cell haemoglobin may involve the immune system....lifi District of coastal Kenya, they found that th... 10, and then declined. , It is estimated that cas...
...e immune system,s pro-inflammatory response to bac... with an enzyme called inducible nitric oxide synt...gical Chemistry, scientists report that the predom...ic oxide synthase, is also involved in nitric oxid...ery may eventually provide a new target to treat s...
Other Biology News:New Estimates For The Causes Of Child Deaths Worldwide 2Researchers report new pro-inflammatory role for anti-inflammatory enzyme 2
ALTO-8 (Integration friendly version) from ABgene
ALTO-8 (Bench top Version) from ABgene
...AcTEV Protease is an enhanced form of Tobacco Etch..., highly active, and significantly more stable tha...vity. AcTEV Protease specifically recognizes a sev...ng between Gln and Gly), making it useful for remo...
...The Heraeus HERAcell is the ideal CO2 incubator fo...of ova or embryos at or near body temperature. HER...ide everything needed to protect and grow your val...ditions ensure optimum culture growth. , ContraCo...
Biology Products: